K4 Elite
K4 Elite
Selank is a synthetic tuftsin analogue developed in Russia and studied there as an intranasal anxiolytic. The indexed human evidence consists of Russian-language comparative clinical studies (2008-2015) in generalised anxiety disorder, neurasthenia and anxiety-phobic/somatoform disorders, benchmarked against benzodiazepines (medazepam, phenazepam) rather than placebo, plus one placebo-controlled fMRI study in healthy volunteers. Doses and routes are not reported in most English abstracts, and no Western replication has been published.
Each row records what a published study did: who it enrolled, the regimen it administered to those subjects, and what it reported. These are historical study descriptions, not protocols to follow.
| Study | Population | Regimen as reported | Primary findings |
|---|---|---|---|
| Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008 (comparative study vs medazepam; Russian-language) | 62 patients with generalised anxiety disorder or neurasthenia (Selank n=30; medazepam n=32) | Patients received Selank or medazepam; dose, route and duration are not stated in the English abstract. Serum enkephalin activity was measured alongside Hamilton, Zung and CGI scales. | Anxiolytic effects were reported as similar between Selank and medazepam; the authors additionally described antiasthenic and psychostimulant effects with Selank, and an increase in leu-enkephalin half-life during treatment. |
| Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014 (comparative study vs phenazepam; Russian-language) | 60 patients with anxiety-phobic and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1) | Patients received Selank or phenazepam; dose and duration are not stated in the English abstract. | The authors reported an anxiolytic effect with a mild nootropic component for Selank, persisting for about a week after the last administration. |
| Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2015 (add-on study; Russian-language) | 70 patients with anxiety-phobic, hypochondriac and somatoform disorders (phenazepam alone n=30; Selank plus phenazepam n=40) | Patients received phenazepam monotherapy or phenazepam plus Selank; tolerability was rated on the UKU scale and cognition with Stroop and verbal fluency tests. Selank dose is not stated in the English abstract. | Combined treatment was reported to reduce phenazepam-associated side effects (attention/memory impairment, asthenia, sedation, orthostatism) during treatment and after benzodiazepine withdrawal. |
| Uchakina et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008 (Russian-language) | Patients with generalised anxiety disorder and neurasthenia | Patients received Selank for 14 days; serum Th1/Th2 cytokine balance was measured before and after. | Changes in serum Th1/Th2 cytokine balance were reported over 14 days of treatment; in vitro, Selank suppressed IL-6 gene expression in blood cells from depressed patients. |
| Panikratova et al., Dokl Biochem Biophys 2020 (placebo-controlled resting-state fMRI study) | 52 healthy participants | Participants received a single administration of Selank, Semax or placebo; resting-state fMRI was acquired before and 5 and 20 minutes after administration (dose not stated in the abstract). | Between-group differences in functional connectivity between the right amygdala and right temporal cortex were reported after Selank or Semax compared with placebo. |
Effects recorded in the cited reports. Frequencies are those the source reported, in the population that source studied.
| Effect | Frequency / context | Source |
|---|---|---|
| Tolerability relative to benzodiazepines | In Medvedev 2014 (n=60) Selank was compared with phenazepam on tolerability; the English abstract reports no specific Selank adverse-event rates. Zozulya 2001 described Selank as not causing the side effects characteristic of most anxiolytics; no quantitative safety data are given. | [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] ↗ |
Interactions documented in trial reports, prescribing information or pharmacology references.
| Agent | Type | Note | Source |
|---|---|---|---|
| Phenazepam (benzodiazepine) | pharmacodynamic (studied combination) | Selank was co-administered with phenazepam in 40 patients; the authors reported fewer benzodiazepine-type side effects with the combination than with phenazepam alone (Medvedev 2015). | [Optimization of the treatment of anxiety disorders with selank] ↗ |
No contraindications with a verifiable citation have been indexed for this compound.